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The effects of dyslipidemia on the risk of type 2
diabetes (T2D) and related traits are not clear. We
used regression models and 140 lipid-associated
genetic variants to estimate associations between
circulating HDL cholesterol (HDL-C), LDL cholesterol
(LDL-C), and triglycerides and T2D and related traits.
Each genetic test was corrected for effects of var-
iants on the other two lipid types and surrogates of
adiposity. We used the largest data sets available:
34,840 T2D case and 114,981 control subjects from
the DIAGRAM (DIAbetes Genetics Replication And
Meta-analysis) consortium and up to 133,010 individ-
uals without diabetes for insulin secretion and sensi-
tivity from the MAGIC (Meta-Analyses of Glucose and
Insulin-related traits Consortium) and GENESIS
(GENEticS of Insulin Sensitivity) studies. Eight of 21
associations between groups of variants and diabetes
traits were signiﬁcant at the nominal level, including
those between genetically determined lower HDL-C (b =
20.12, P = 0.03) and T2D and genetically determined
lower LDL-C (b =20.21, P = 53 1026) and T2D. Although
some of these may represent causal associations, we
discuss why caution must be used when using Mende-
lian randomization in the context of circulating lipid lev-
els and diabetes traits. In conclusion, we found evidence
of links between genetic variants associated with lipids
and T2D, but deeper knowledge of the underlying ge-
netic mechanisms of speciﬁc lipid variants is needed
before drawing deﬁnite conclusions about causality
based on Mendelian randomization methodology.
Type 2 diabetes is associated with dyslipidemia (i.e.,
higher circulating concentrations of triglycerides and
small, dense LDL cholesterol [LDL-C] and lower concen-
trations of HDL cholesterol [HDL-C]), but the causal
relationship between dyslipidemia and type 2 diabetes has
been difﬁcult to disentangle (1). Most evidence suggests
that altered lipid concentrations are secondary to insulin
resistance (2) or other factors associated with both lipids
and diabetes (e.g., adiposity), but some studies suggest
that dyslipidemia could contribute to the pathogenesis
of type 2 diabetes (3) through mechanisms related to
impaired protection of b-cells or endoplasmic reticulum
stress (4). Other studies of carriers of loss-of-function
mutations in the ABCA1 gene have demonstrated that
altered cholesterol concentrations could affect insulin se-
cretion in humans, although with conﬂicting results Q:3(5,6).
The relationship between lipid levels and diabetes is
further complicated by the apparently causal link between
statin therapy and increased risk of type 2 diabetes. A
meta-analysis of randomized controlled trials and Men-
delian randomization analysis (7) showed that statin
treatment results in a slightly increased risk of diabetes.
The Mendelian randomization study showed that a com-
mon allele in the 3-hydroxy-3-methylglutaryl-CoA reduc-
tase (HMGCR) gene (encoding the target of statins)
associated with lower LDL-C was also associated with
a higher risk of diabetes and that this risk is potentially
mediated through a slight increase in BMI. The mecha-
nism by which statins could increase the risk of diabetes is
not known, but other theories include direct effects of
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statins on insulin secretion, reduced translocation of
GLUT-4 to membranes in target tissues, and reduced in-
tracellular signaling (7,8).
Several studies have used a Mendelian randomization
approach to assess the causal relationship between
circulating lipids and type 2 diabetes, but these inves-
tigations included a relatively small number of studies and
individuals and produced conﬂicting results. One study
in 2,447 individuals with diabetes and 3,052 without
diabetes found associations between genetically deter-
mined higher concentrations of triglycerides and lower
concentrations of HDL-C and increased risk of type 2
diabetes (9). A larger study in 5,637 individuals with
diabetes and up to 8,271 without diabetes using fewer
genetic variants found no association between geneti-
cally determined higher concentrations of triglycerides
and diabetes-related outcomes (10).
Mendelian randomization studies usually require large
sample sizes because genetic variants explain only a small
fraction of the primary traits under investigation. In the
current study, we aimed to use genetic variants to
investigate the relationships between circulating lipid
fractions and type 2 diabetes by using all available data.
These data included the latest genome-wide association
study (GWAS) meta-analyses of 34,840 individuals with
type 2 diabetes and 114,981 control subjects (11) and up
to 133,010 individuals with intermediate trait measures
(12,13). We assessed whether genetic variants associated
with life-long differences in circulating triglyceride, HDL-
C, and LDL-C levels were related to risk for type 2
diabetes and diabetes-related phenotypes, including intra-
venous measurements of insulin sensitivity. In this con-
text, we also discuss the limitations of the Mendelian
randomization approach when using single nucleotide
polymorphisms (SNPs) that could be associated with mul-
tiple metabolic traits.
RESEARCH DESIGN AND METHODS
Genetic Instruments
To create genetic instruments, we selected 185 indepen-
dent (linkage disequilibrium r2 , 0.05) SNPs from 157
loci associated with triglycerides, HDL-C, and/or LDL-C in
the most recent meta-analysis of circulating lipid concen-
trations in 188,577 participants (14). We started from the
185 SNPs as in Do et al. (15), who assessed the associa-
tion between genetically determined lipid concentrations
and coronary heart disease.
We excluded those SNPs associated at P , 1024 with
the major confounding phenotypes BMI and waist-to-hip
ratio adjusted for BMI (WHRadjBMI) (i.e., SNPs could be
assumed to be primarily associated with these pheno-
types) or that were associated with the outcomes (type
2 diabetes or glycemic traits) with effect sizes of .2 SDs
greater than the average lipid SNP (i.e., SNPs could be
assumed to be primarily associated with the outcome
rather than lipid levels [see Supplementary Fig. 1 for an
example and Supplementary Table 1 for a full list]). For all
downstream analyses, we used a primary set of the
remaining 140 SNPs as well as secondary sets of SNPs
for sensitivity analyses, as follows:
1) A subset of these 140 SNPs after excluding single SNPs
with disproportionately large contributions to the
overall model as deﬁned by the absolute difference of
ﬁts (DFITS) model described in the STATISTICAL ANALYSIS
section
2) Lipid-speciﬁc subsets of these 140 SNPs with relatively
larger effects on the lipid fraction of interest (.0.01
SD units) and smaller effects on both the other two
lipid fractions (,0.01 SD units)
3) Subsets of SNPs identiﬁed through agglomerative hier-
archical clustering as described in the STATISTICAL ANALYSIS
section
All included SNPs and their proxies are shown in Sup-
plementary Table 2.
Association of Lipid-Associated SNPs With Lipid Traits
We used the effect sizes of each SNP on triglycerides,
HDL-C, and LDL-C from published data (14,15) wherein
the per-allele effects on each lipid trait were reported in
SD units based on inverse normal transformed residuals
of lipid concentrations after adjustment for age and sex.
For the largest cohort (deCODE genetics, n = 15,612), the
reported SD units per lipid trait were HDL-C, 17.9 mg/dL;
LDL-C, 39.9 mg/dL; and triglycerides, 81.8 mg/dL.
Association of Lipid-Associated SNPs With Diabetes
and Diabetes-Related Traits
The effect estimates of each lipid SNP on type 2 diabetes
and diabetes-related traits were obtained from GWAS
meta-analysis results using the largest study sizes avail-
able. The effect on type 2 diabetes risk was estimated by
the DIAbetes Genetics Replication And Meta-analysis
(DIAGRAM) consortium, including 34,840 case and
114,981 control subjects (11). The effect estimate of
each lipid SNP on measures of glucose homeostasis was
based on associations with fasting glucose in up to
133,010 participants without diabetes and 2-h glucose
after an oral glucose tolerance test (OGTT) in up to
42,854 participants from the Meta-Analyses of Glucose
and Insulin-related traits Consortium (MAGIC) (12).
The effect of each lipid SNP on insulin sensitivity was
retrieved from the following meta-analyses: 1) insulin
sensitivity based on intravenous measurement methods
from the GENEticS of Insulin Sensitivity (GENESIS) con-
sortium (n = 2,764) (Supplementary Data), 2) insulin sen-
sitivity index (ISI) = 10,000 / =[fasting plasma glucose
(mg/dL) 3 fasting insulin 3 mean glucose during OGTT
(mg/dL) 3 mean insulin during OGTT] from an OGTT in
up to 10,147 participants without diabetes from MAGIC
(13), and 3) fasting insulin (transformed to the natural
logarithm scale) from up to 108,557 participants without
diabetes from MAGIC (12). The SNP effects on insulin
secretion were based on the OGTT-based disposition index
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[(100 3 insulin at 30 min) / (glucose at 30 min 3 [glucose
at 30 min – 3.89])3 ISI] in up to 10,505 participants from
MAGIC (13).
We retrieved the effect estimates of each lipid SNP on
BMI and WHRadjBMI from the Genetic Investigation of
ANthropometric Traits (GIANT) consortium based on up
to 249,796 individuals for BMI (16) and up to 77,167 for
WHRadjBMI (17).
The alleles were aligned so that the effect allele was
consistent across all phenotypes. When a SNP was not
available, the proxy SNP with highest r2 with the lead
SNP according to HapMap2 release #24 was selected (in-
cluding only proxies with r2 $ 0.9). We used phased CEU
(Utah residents with Northern and Western European
ancestry) haplotypes from HapMap2 release #24, build
36 (http://hapmap.ncbi.nlm.nih.gov), to identify the al-
lele corresponding to the lipid-increasing allele reported
by Do et al. (15). For some phenotypes, no information
was available for lead or proxy SNPs; hence, the number
of SNPs included in each analysis varied slightly.
Statistical Analysis
Primary Analysis
For the analysis of the genetic association between
circulating lipids and type 2 diabetes and diabetes-related
traits, we used the framework proposed by Do et al. (15).
For each outcome of interest, we used linear regression
models with the SNP effect sizes on the lipid of interest
(blipid) as the independent variable and the outcome of
interest as the dependent variable (here, ln odds ratio for
diabetes and b for related continuous traits [boutcome]). If
a linear relation between blipid and boutcome is observed,
causal inference can be drawn under certain assumptions,
such as no population stratiﬁcation, pleiotropy, or ascer-
tainment bias. Because some lipid SNPs are associated
with several lipid fractions, we ran the models with and
without additional adjustment for the SNP effect on the
other lipid fractions (in the same way as Do et al.) and for
the SNP effects on BMI and WHRadjBMI (as some SNPs
have ambiguous primary effects on lipids and these sur-
rogate measures of adiposity). We used a Bonferroni-
corrected a-threshold of 0.002 given that we analyzed
seven outcome traits for three lipid fractions (0.05/21 =
0.002).
Subset of Lipid SNPs Excluding Those With
Disproportionately Large Contributions
We also evaluated whether single SNPs with high
inﬂuence on the primary analysis models as estimated
by DFITS, as deﬁned by Belsley et al. (18), were critical
for the model results by rerunning the models without
SNPs with absolute DFITS .0.4 [2=([k + 1] / [n 2 k 2
1])], where k is the number of predictors and n is the
number of observations (here SNPs) (18). However, even
with this approach, we note that we could not account
for all sources of pleiotropy for reasons we expand on in
the discussion.
Subsets of SNPs With More Lipid-Speciﬁc Associations
In sensitivity analyses, we constructed genetic risk scores
for individual lipid fractions based on subsets of SNPs
with relatively large effects on the lipid fraction of
interest (.0.01 SD units) and smaller effects on other
lipid fractions (,0.01 SD units). This approach resulted
in genetic risk scores of 5, 23, and 26 SNPs for triglycer-
ides, HDL-C, and LDL-C, respectively (Supplementary Ta-
ble 2). These more-speciﬁc risk scores explained 0.2, 0.9,
and 1.0% of the variance in their respective lipid levels,
whereas the 140 SNP scores explained 3.7, 5.8, and 6.6%
for triglycerides, HDL-C, and LDL-C, respectively. Because
of the small number of genetic variants and amount of
phenotypic variance explained by the ﬁve triglyceride
SNPs, we did not pursue this analysis any further. We
then assessed the association of these scores with type
2 diabetes and diabetes-related traits on summary-level
data using the method described by Dastani et al. (19)
implemented in the R package gtx. Brieﬂy, the effect of
each of the three lipid scores on diabetes and related
traits was calculated as Eq. 1:
∑ ​ wibis
2 2
i

∑ ​ wi2s2 2i (Eq. 1)
where bi is the effect of the lipid-increasing alleles on
diabetes, si its corresponding SE, and wi the SNP effect
on the respective lipid. We used the equation 2pq 3 b2 to
estimate the variance explained by the different scores,
where p and q are the allele frequencies for the major and
minor alleles and b the estimated effect size.
Subsets of Lipid SNPs Identiﬁed Through Clustering
Methods
We used hierarchical clustering analysis to group 140
SNPs based on their effect on HDL-C, LDL-C, and
triglycerides. We used Euclidean metrics to calculate
pairwise distance between effect sizes on lipid levels of
the 140 SNPs as input data, and we used Ward as a cluster
method in the R package gplots (Supplementary Fig. 2).
This method has been used before to cluster fasting in-
sulin–associated genetic variants using metabolic traits
(20). We then assessed the impact of each cluster on
type 2 diabetes and related outcomes, using genetic risk
scores weighted on each SNP’s effect on dyslipidemia
[(LDL-C + triglycerides 2 HDL-C) / 3] and calculations
using the method described by Dastani et al. (19) (see
previous section on subsets of more lipid-speciﬁc SNPs).
RESULTS
Associations Between Genetically Determined HDL-C
Levels and Diabetes Traits
Primary Analysis
We did not identify consistent associations between
genetically higher circulating HDL-C and risk of type 2
diabetes as assessed by the 140-SNP risk score using
HDL-C effect sizes for each SNP (bHDL-C vs. bdiabetes). In
an unadjusted model, we observed a borderline association
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between genetically higher HDL-C and lower risk of type
2 diabetes (b = 20.15, P = 2 3 1023), but this associ-
ation was attenuated after adjusting for the effects on
other lipids and surrogates of adiposity (b = 20.12, P =
0.03) (Table 1). Note that the coefﬁcients can be inter-
preted as the estimated causal effect associated with
a 1-SD unit increase in HDL-C. Hence, we estimated
that a 1-SD unit increase of HDL-C was associated
with an 11% reduction of relative risk of diabetes
(odds ratio = e20.12 = 0.89).
We did not identify consistent associations between
genetically higher circulating HDL-C (bHDL-C) and inter-
mediate measures of glycemia in individuals without di-
abetes. The HDL-C (bHDL-C) risk score was associated with
lower fasting glucose (bglucose) in unadjusted models (b =
20.04, P = 43 1025), but this association was attenuated
when adjusting for the effects of SNPs on the other two
lipid types and surrogates of adiposity (b =20.03, P = 33
1023). There was no association with glucose-stimulated
measures of insulin secretion (disposition index). No
associations were found between genetically higher circu-
lating HDL-C and measures of insulin sensitivity by OGTT
or by intravenous measurements or fasting insulin in
adjusted models.
Subsets of Lipid SNPs Excluding Those With
Disproportionately Large Contributions
We evaluated the impact of removing single inﬂuential
SNPs by rerunning the fully adjusted models excluding
the 8–13 SNPs with absolute DFITS .0.4. We found
similar b-estimates, but the estimates for type 2 diabe-
tes and fasting glucose no longer reached the Bonfer-
roni-corrected level of signiﬁcance. In this analysis, we
found a positive association between HDL-C (as
assessed by genetic variants) and insulin sensitivity by
OGTT (Table 2).
Subsets of SNPs With More Lipid-Speciﬁc Associations
The nominal association between genetically higher
circulating HDL-C and lower risk of type 2 diabetes was
consistent in a sensitivity analysis of 23 SNPs with
disproportionately strong associations with HDL-C com-
pared with triglycerides and LDL-C, although the strength
of signiﬁcance was reduced (b =20.19, P = 0.04). We also
observed an association between higher HDL-C genetic
risk score and lower disposition index (lower insulin se-
cretion), which was not observed in the main analysis of
140 SNPs, but this result is inconsistent with the HDL-C
risk score – type 2 diabetes association. There was no
evidence of association between genetically higher circu-
lating HDL-C and any other glycemic measures in the
sensitivity analyses (Table 3).
Subsets of Lipid SNPs Identiﬁed Through Clustering
Methods
We next analyzed a genetic risk score consisting of SNPs
that clustered together as a group where HDL-C–lowering
alleles tended to associate with neutral or positive effects
on LDL-C and triglycerides (black cluster in Supple-
mentary Fig. 2). Results from this set of SNPs were
consistent with the main and other secondary analysis:
The group of SNPs where alleles were associated with
lower HDL-C concentrations was associated with in-
creased risk of type 2 diabetes, raised fasting glucose
levels, and lowered insulin sensitivity (Supplementary
Table 3).
Associations Between Genetically Determined LDL-C
Levels and Diabetes Traits
Primary Analysis
We identiﬁed an association between genetically higher
circulating LDL-C and lower risk of type 2 diabetes as
assessed by the 140-SNP risk score using LDL-C effect
sizes for each SNP (bLDL-C vs. bdiabetes) in the unadjusted
model (b = 20.14, P = 1 3 1023) and even more strongly
after adjusting for effects on other lipids and surrogates
of adiposity (b = 20.21, P = 5 3 1026) (Table 1). We did
not identify consistent associations between genetically
higher circulating LDL-C (bLDL-C) and intermediate glyce-
mic traits, although there was a nominal association with
lower fasting glucose in individuals without diabetes
(bglucose vs. bdiabetes [b = 20.02, P = 0.01]) in models
adjusted for the other two lipid fractions and surrogates
of adiposity. There were no associations with measures of
stimulated insulin secretion or insulin sensitivity in the
analyses.
Subsets of Lipid SNPs Excluding Those With
Disproportionately Large Contributions
We evaluated the impact of removing single inﬂuential
SNPs by rerunning the fully adjusted models excluding
the 8–13 SNPs with absolute DFITS .0.4. We found sim-
ilar results in this analysis as in the primary analysis
(Table 2).
Subsets of SNPs With More Lipid-Speciﬁc Associations
The strength of the association of LDL-C and type 2
diabetes was dramatically smaller (and statistically
nonsigniﬁcant) in a sensitivity analysis including 26
SNPs with disproportionately strong associations with
LDL-C compared with triglycerides and HDL-C. There
were no associations with measures of stimulated
insulin secretion or insulin sensitivity in the analyses
(Table 3).
Subsets of Lipid SNPs Identiﬁed Through Clustering
Methods
We next analyzed a genetic risk score consisting of SNPs
that clustered together as a group where LDL-C–raising
alleles tended to associate with weak positive effects on
triglycerides and largely neutral effects on HDL-C (red
cluster in Supplementary Fig. 2). Results from this set
of SNPs were consistent with other results: The group
of SNPs where alleles associated with higher LDL-C was
associated with a lower risk of type 2 diabetes (Supple-
mentary Table 3). A third cluster of SNPs contained
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weakly LDL-C–lowering or neutral alleles, and these
alleles tended to have neutral effects on HDL-C and
weak negative or neutral effects on triglycerides. This
cluster of SNPs was not associated with any diabetes-
related traits (Supplementary Table 3 and green cluster
in Supplementary Fig. 2).
Associations Between Genetically Determined
Triglyceride Levels and Diabetes Traits
Primary Analysis
We did not identify any consistent associations between
genetically higher circulating triglycerides and higher
risk of type 2 diabetes as assessed by the 140-SNP risk
score using triglyceride effect sizes for each SNP
(btriglycerides vs. bdiabetes). We observed only very slight
trends of association between genetically higher circu-
lating triglycerides and higher risk of type 2 diabetes
(b = 0.13, P = 0.04) and higher fasting glucose (bglucose
[b = 0.02, P = 0.04]) and insulin (binsulin [b = 0.03, P =
0.03]) in individuals without diabetes in adjusted mod-
els. There were no associations with measures of stim-
ulated insulin secretion or other measures of insulin
sensitivity (Table 1).
Subsets of Lipid SNPs Excluding Those With
Disproportionately Large Contributions
We evaluated the impact of removing single inﬂuential
SNPs by rerunning the fully adjusted models excluding
the 8–13 SNPs with absolute DFITS.0.4. In this analysis,
the trends of associations were abolished for type 2 di-
abetes and insulin (Table 2).
DISCUSSION
This study represents the most comprehensive genetic
analysis of the role of the three main circulating lipid
fractions in type 2 diabetes and related glycemic traits.
We used results from the largest GWASs and 140
common genetic variants robustly associated with lipid
fractions. In contrast, previous studies used a maximum
of 5,637 case subjects with type 2 diabetic and 67 SNPs
(9,10). The current results, therefore, add to the debate
about the role of lipids in type 2 diabetes and highlight
the complexities in using genetic risk scores and a Mende-
lian randomization approach to dissect directions of cau-
sality in complex metabolic traits and when potential
pleiotropic effects or confounders exist.
Despite using data from the largest GWASs available,
we did not identify consistent evidence for a causal role of
circulating lipids in type 2 diabetes. We also did not
identify consistent evidence for a causal role of circulating
lipids with high glucose levels, insulin secretion, or insulin
sensitivity measures in individuals without diabetes.
We observed 8 of 21 associations reaching a nominal
P , 0.05. The traits studied are correlated with one an-
other, which could explain an inﬂation of low P values.
The associations were mainly observed for traits with
large sample sizes (type 2 diabetes, fasting insulin, fasting
glucose), and we may not have had adequate statistical
Table 2—Comparison of original models with models excluding SNPs with high inﬂuence as measured by DFITS
Original model Model excluding all SNPs with absolute DFITS .0.4
Outcome b (95% CI) P value No. SNPs b (95% CI) P value No. SNPs
HDL-C
Type 2 diabetes 20.12 (20.24, 20.01) 0.03 139 20.17 (20.28, 20.05) 0.01 128
Fasting glucose 20.03 (20.05, 20.01) 3.4 3 1023 134 20.03 (20.05, 20.01) 0.01 126
2-h post-OGTT glucose 20.03 (20.12, 0.06) 0.52 134 20.05 (20.14, 0.04) 0.30 126
Insulin sensitivity* 0.13 (20.04, 0.31) 0.15 140 0.13 (20.03, 0.3) 0.12 132
ISI from OGTT 0.13 (0.03, 0.22) 0.01 140 0.16 (0.07, 0.25) 5.1 3 1024 127
Fasting insulin 20.01 (20.03, 0.01) 0.25 134 20.01 (20.04, 0.01) 0.27 126
Disposition index 0.01 (20.09, 0.11) 0.84 140 20.01 (20.11, 0.09) 0.83 132
LDL-C
Type 2 diabetes 20.21 (20.29, 20.12) 5.0 3 1026 139 20.23 (20.32, 20.14) 2.0 3 1026 128
Fasting glucose 20.02 (20.04, 20.01) 5.6 3 1023 134 20.02 (20.04, 20.01) 4.8 3 1023 126
2-h post-OGTT glucose 20.02 (20.09, 0.05) 0.59 134 20.02 (20.09, 0.05) 0.62 126
Insulin sensitivity* 0.01 (20.14, 0.15) 0.93 140 0.03 (20.1, 0.17) 0.64 132
ISI from OGTT 0 (20.08, 0.08) 0.98 140 0.03 (20.04, 0.11) 0.40 127
Fasting insulin 20.01 (20.03, 0) 0.13 134 20.01 (20.03, 0.01) 0.32 126
Disposition index 0.04 (20.04, 0.12) 0.31 140 0.06 (20.02, 0.14) 0.16 132
Triglycerides
Type 2 diabetes 0.13 (0.01, 0.25) 0.04 139 0.05 (20.11, 0.21) 0.53 128
Fasting glucose 0.02 (0, 0.04) 0.04 134 0.02 (0, 0.04) 0.02 126
2-h post-OGTT glucose 0.01 (20.09, 0.11) 0.78 134 20.08 (20.23, 0.08) 0.33 126
Insulin sensitivity* 0.05 (20.15, 0.24) 0.63 140 20.01 (20.28, 0.26) 0.95 132
ISI from OGTT 0.07 (20.04, 0.17) 0.21 140 0.1 (20.06, 0.25) 0.22 127
Fasting insulin 0.03 (0, 0.05) 0.03 134 0.02 (20.01, 0.05) 0.24 126
Disposition index 20.01 (20.12, 0.1) 0.86 140 20.04 (20.14, 0.07) 0.50 132
Models are fully adjusted for SNP effects on other lipid fractions and anthropometry. b (95% CI), b-coefﬁcient with a 95% CI for
correlation of blipid with boutcome. *Insulin sensitivity measured with euglycemic-hyperinsulinemic clamp or insulin stimulation test.
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power for more-speciﬁc measures of insulin secretion and
sensitivity. However, even the eight associations that
reached nominal signiﬁcance either weakened when
adjusting for the effects of the SNPs on other lipids
(HDL-C), weakened in sensitivity analyses (LDL-C), or
could be susceptible to unaccounted-for confounding fac-
tors and biases (especially LDL-C).
We believe that the association between the HDL-C
genetic risk score and type 2 diabetes is worthy of follow-
up. The associations between HDL-C variants and type 2
diabetes and fasting glucose became weaker upon adjust-
ment for other lipids and adiposity but remained
signiﬁcant when analyzing a subset of SNPs with larger
effects on HDL-C. The HDL-C associations are also
consistent with results from monogenic studies. There
is prior genetic evidence for the causal role of HDL-C; for
example, the rare mutations in the ABCA1 gene that cause
Tangier disease primarily cause low levels of circulating
HDL-C and are associated with alterations in insulin se-
cretion in humans (5,6).
The strongest association we found was that between
genetically higher circulating LDL-C levels and lower risk
of type 2 diabetes. This association is consistent with the
recent ﬁnding of Swerdlow et al. (7) of an association
between the LDL-lowering allele in the HMGCR gene
(encoding the target for statins) and increased risk of
type 2 diabetes. However, this association was attenuated
in one of the present sensitivity analyses. We did not
include the HMGCR variant in any of the analyses because
it is associated with BMI, and this association with adi-
posity may explain the differences between the current
results when using the more-speciﬁc set of LDL-C variants
and the results of Swerdlow et al.
In some cases, we observed a discrepancy between the
main analysis and the secondary analysis, most notably
for the LDL-C effect on type 2 diabetes and glucose, as
well as for the HDL-C effect on insulin secretion as
measured by the disposition index. These discrepancies
may be partly due to a relative lack of statistical power in
the secondary analysis but could also be due to bias from
residual pleiotropic effects.
The LDL-C-diabetes association may represent a genu-
ine causal relationship and provides an opportunity to
discuss some of the limitations of using SNPs affecting
lipids in Mendelian randomization analyses. There are
several ways in which associations between lipid SNPs and
diabetes could be confounded or biased. First, carrying
a larger number of LDL-C–raising alleles will increase the
chances of a person requiring statin therapy. Because sta-
tin therapy appears to causally increase the risk of type 2
diabetes, this could result in a noncausal association be-
tween genetically higher LDL-C and an increased risk of
diabetes. However, we saw the opposite association, sug-
gesting that such confounding was not the explanation of
the ﬁndings. Second, carrying a larger number of LDL-C–
raising alleles may have increased the risk of dying of
a heart attack in patients with type 2 diabetes or patients
too ill to participate in a study relative to survival chances
in patients without diabetes Q:4. This survival bias could re-
sult in a noncausal association between genetically higher
LDL-C and reduced risk of diabetes because study partic-
ipants with diabetes may be depleted of LDL-C–raising
alleles and could explain the current association. Future
studies using longitudinal cohorts may help to solve this
issue. Third, it is possible that the LDL-C effect of any
lipid SNP on diabetes-related outcomes is underestimated
because an LDL-C–raising SNP is more likely to result in
statin therapy, which will lower LDL-C effects. Fourth,
accounting for pleiotropic effects is extremely difﬁcult.
We used several approaches to minimize the inﬂuence
of pleiotropy, but it is unlikely that we accounted fully
for its effects, and when we did use a more LDL-C–speciﬁc
Table 3—Results from sensitivity analyses using subsets of lipid fraction–speciﬁc SNPs
Outcome b (95% CI) P value No. SNPs
HDL-C
Type 2 diabetes 20.19 (20.38, 20.01) 0.04 23
Fasting glucose 20.02 (20.06, 0.01) 0.24 21
2-h post-OGTT glucose 0.10 (20.09, 0.28) 0.3 21
Insulin sensitivity* 20.08 (20.5, 0.34) 0.72 23
ISI from OGTT 0.05 (20.18, 0.27) 0.69 23
Fasting insulin 20.02 (20.06, 0.02) 0.27 21
Disposition index 20.36 (20.58, 20.14) 1.0 3 1023 23
LDL-C
Type 2 diabetes 20.03 (20.19, 0.12) 0.67 26
Fasting glucose 0 (20.03, 0.03) 0.85 23
2-h post-OGTT glucose 0.13 (20.04, 0.29) 0.14 23
Insulin sensitivity* 20.04 (20.41, 0.33) 0.83 26
ISI from OGTT 0.08 (20.13, 0.28) 0.45 26
Fasting insulin 0.02 (20.01, 0.06) 0.21 23
Disposition index 0.05 (20.15, 0.25) 0.61 26
b (95% CI), b-coefﬁcient with a 95% CI for correlation of blipid with boutcome. *Insulin sensitivity measured with euglycemic-hyper-
insulinemic clamp or insulin stimulation test.
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set of SNPs, the associations with diabetes were attenu-
ated. We had to exclude 24% of SNPs (45 of 185) with
known likely pleiotropic effects, which raises the like-
lihood that other SNPs have unknown pleiotropic effects.
Although we accounted for other lipids and surrogate
measures of adiposity, including BMI and waist-to-hip
ratio, we did not account fully for SNPs that may have
primary effects on insulin resistance because insulin re-
sistance is one of the main traits along a potential causal
pathway (12,20). These issues have been discussed in a re-
cent article by Burgess et al. (21) that proposed to reas-
sess models excluding SNPs with disproportionate effects
on outcome compared with their effects on lipids. We
excluded SNPs with disproportionately large effects on
diabetes-related outcomes, but SNPs primarily associated
with insulin sensitivity remained in the analysisQ:5 . Includ-
ing only SNPs where the exact causal gene and role in lipid
metabolism is not currently feasible because too little is
currently known about the exact mechanisms of most
SNPs, and as a result, such analyses would be underpow-
ered. Finally, we did not have information about the ef-
fect of the included SNPs on more-speciﬁc lipid moieties
and fractions, such as various free fatty acids, and we
cannot exclude that the investigated SNPs have a primary
effect on these moieties rather than on the investigated
lipid fractions.
In conclusion, we used the largest data sets available
(140 lipid SNPs, 34,840 individuals with diabetes, and up
to 133,010 individuals without diabetes) and found
evidence of an inverse association of both genetically
determined HDL-C and LDL-C with type 2 diabetes.
However, as discussed in detail, these associations could
be caused by survival bias, pleiotropy, or unknown
confounding factors and should be interpreted with
caution.
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